Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 189

Similar articles for PubMed (Select 21649692)

1.

Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.

Foissac F, Blanche S, Dollfus C, Hirt D, Firtion G, Laurent C, Treluyer JM, Urien S.

Br J Clin Pharmacol. 2011 Dec;72(6):940-7. doi: 10.1111/j.1365-2125.2011.04035.x.

2.

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions.

Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. Epub 2007 Nov 19.

3.

Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.

Bunupuradah T, Techasaensiri C, Keadpudsa S, Thammajaruk N, Srimuan A, Sahakijpicharn T, Prasitsuebsai W, Ananworanich J, Puthanakit T; HIV-NAT 146 Study Team.

Pediatr Infect Dis J. 2014 Dec;33(12):e316-9. doi: 10.1097/INF.0000000000000469.

PMID:
24983717
4.

Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.

Wang X, Boffito M, Zhang J, Chung E, Zhu L, Wu Y, Patterson K, Kashuba A, Tebas P, Child M, Mahnke L, Bertz R.

AIDS Patient Care STDS. 2011 Sep;25(9):509-15. doi: 10.1089/apc.2011.0113. Epub 2011 Jul 19.

5.

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.

Ther Drug Monit. 2007 Oct;29(5):648-51.

PMID:
17898658
6.

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.

von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S.

Eur J Clin Pharmacol. 2007 Oct;63(10):935-40. Epub 2007 Jul 31.

PMID:
17665183
7.

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):201-5.

PMID:
17414932
8.

Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.

Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back D, Khoo S, Davies G.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):60-6. doi: 10.1097/QAI.0b013e3182737231.

9.

Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.

Kiser JJ, Rutstein RM, Samson P, Graham B, Aldrovandi G, Mofenson LM, Smith E, Schnittman S, Fenton T, Brundage RC, Fletcher CV.

AIDS. 2011 Jul 31;25(12):1489-96. doi: 10.1097/QAD.0b013e328348fc41.

10.

Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.

Bertz RJ, Persson A, Chung E, Zhu L, Zhang J, McGrath D, Grasela D.

Pharmacotherapy. 2013 Mar;33(3):284-94. doi: 10.1002/phar.1205.

PMID:
23456732
11.

Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.

Hong Y, Kowalski KG, Zhang J, Zhu L, Horga M, Bertz R, Pfister M, Roy A.

Antimicrob Agents Chemother. 2011 Dec;55(12):5746-52. doi: 10.1128/AAC.00554-11. Epub 2011 Sep 19.

12.

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.

Dickinson L, Boffito M, Back D, Waters L, Else L, Davies G, Khoo S, Pozniak A, Aarons L.

J Antimicrob Chemother. 2009 Jun;63(6):1233-43. doi: 10.1093/jac/dkp102. Epub 2009 Mar 28.

13.

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.

Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C.

Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8. Epub 2006 Aug 28.

14.

Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir.

Fournier C, Higgins N, Thomas R, Baril JG, Thibeault D, Lalonde R, Sheehan NL.

Ther Drug Monit. 2013 Apr;35(2):264-9. doi: 10.1097/FTD.0b013e3182834057.

PMID:
23503454
15.

Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.

Rodríguez-Nóvoa S, Morello J, Barreiro P, Maida I, García-Gascó P, Vispo E, González-Pardo G, Parra A, Jiménez-Nácher I, Soriano V.

AIDS Res Hum Retroviruses. 2008 Jun;24(6):821-5. doi: 10.1089/aid.2007.0276.

PMID:
18507524
16.
17.

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Le Tiec C, Barrail A, Goujard C, Taburet AM.

Clin Pharmacokinet. 2005;44(10):1035-50. Review.

PMID:
16176117
18.

Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.

Moyle GJ, Hardy H, Farajallah A, DeGrosky M, McGrath D.

Clin Drug Investig. 2014 Apr;34(4):287-96. doi: 10.1007/s40261-014-0175-4.

PMID:
24557728
19.

Atazanavir pharmacokinetics with and without tenofovir during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS; IMPAACT 1026s Study Team.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412-9. doi: 10.1097/QAI.0b013e31820fd093.

20.

Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.

Dumond JB, Adams JL, Prince HM, Kendrick RL, Wang R, Jennings SH, Malone S, White N, Sykes C, Corbett AH, Patterson KB, Forrest A, Kashuba AD.

HIV Med. 2013 Aug;14(7):401-9. doi: 10.1111/hiv.12017. Epub 2013 Feb 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk